SCHEMBL9481875

SCHEMBL9481875

CCCCC(C)(C)[C@H](O)/C=C/[C@@H]1[C@@H](C/C=C\CCCC(=O)OC)[C@H](Cl)C[C@H]1O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGFR P43088 3/20 0.68
PTGER3 P43115 3/20 0.68
TBXA2R P21731 2/20 0.68
PTGER1 P34995 2/20 0.68
ALDH1A1 P00352 3/20 0.61
KDM4E B2RXH2 1/20 0.61
HKDC1 Q2TB90 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
SAE1 Q9UBE0 1/20 0.61
UBA2 Q9UBT2 1/20 0.61
PDE4D Q08499 4/20 0.52
PTGER2 P43116 2/20 0.49
PTGIR P43119 1/20 0.49
LMNA P02545 3/20 0.48
PTGER4 P35408 2/20 0.48
PTGDR Q13258 1/20 0.48
SLCO2A1 Q92959 1/20 0.48
HPGD P15428 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9481879 1.00 PTGFR (0.68) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
SCHEMBL11178909 0.92 PTGFR (0.81) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL9847683 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL10803435 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL3873408 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL1554648 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL1554645 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
Nocloprost SCHEMBL436204 0.90 PTGER3 (0.84) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
SCHEMBL11072257 0.89 PTGFR (0.68) PTGFRPTGER3TBXA2RPTGER1ALDH1A1
SCHEMBL10627456 0.89 PTGFR (0.68) PTGFRPTGER3TBXA2RPTGER1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5079259-A PHARMACEUTICALLY ACTIVE 9-CHLOROPROSTAGLANDINS SCHERING AKTIENGESELLSCHAFT (DE) 1992-01-07 US claimed
EP-0030377-B1 9-CHLORO-PROSTAGLANDIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE AS MEDICINES SCHERING AKTIENGESELLSCHAFT (DE) 1984-02-22 EP claimed
EP-0030377-A1 9-Chloro-prostaglandin derivatives, process for their preparation and use as medicines SCHERING AKTIENGESELLSCHAFT (DE) 1981-06-17 EP claimed
US-7563924-B2 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments SCHERING AKTIENGESELLSCHAFT (DE) 2009-07-21 US disclosed
US-20070203096-A1 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments SCHERING AKTIENGESELLSCHAFT (DE) 2007-08-30 US disclosed
US-5204371-A Pharmaceutically active 9-chloroprostaglandins SCHERING AKTIENGESELLSCHAFT (DE) 1993-04-20 US disclosed
US-5079259-A PHARMACEUTICALLY ACTIVE 9-CHLOROPROSTAGLANDINS SCHERING AKTIENGESELLSCHAFT (DE) 1992-01-07 US disclosed
EP-0198829-B1 9-HALOGEN-PROSTAGLANDINE DERIVATIVES, PREPARATION PROCESS AND UTILIZATION THEREOF AS DRUGS SCHERING AKTIENGESELLSCHAFT (DE) 1990-04-18 EP disclosed
EP-0198829-A1 9-HALOGEN-PROSTAGLANDINE DERIVATIVES, PREPARATION PROCESS AND UTILIZATION THEREOF AS DRUGS. SCHERING AG (DE) 1986-10-29 EP disclosed
WO-1985002841-A1 9-HALOGEN-DELTA2-PROSTAGLANDINE DERIVATIVES, PREPARATION PROCESS AND UTILIZATION THEREOF AS DRUGS SCHERING AKTIENGESELLSCHAFT (DE) 1985-07-04 WO disclosed
US-4444788-A Pharmaceutically active 9-chloroprostaglandins SCHERING AKTIENGESELLSCHAFT (DE) 1984-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203096-A1 9-Chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments PGF, PTGIS, CYP11B2 PTGFR 21/4885PTGER3 62/4885TBXA2R 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.